Peroxisome Proliferator-Activated Receptor-Gamma Activation in Peritoneal Dialysis Patients

End-stage Renal Disease Clinical Trial

— PPAR  

Official title:

Targeting Peroxisome Proliferator-Activated Receptor-Gamma in Peritoneal Dialysis Patients - Will it Reduce Inflammation, Atherosclerosis, Calcification and Improve Survival of Peritoneal Dialysis Patients? (PROOF Trial)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00745225
• Other study ID #: A111-101
• Status: Completed
• Phase: Phase 4
• Start date: February 2006
• Est. completion date: December 2014

Study information

• Verified date: October 2021
• Source: The University of Hong Kong
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To study whether peroxisome proliferator-activated receptor-gamma activation in peritoneal dialysis patients will reduce inflammation, atherosclerosis, calcification and improve survival of peritoneal dialysis patients

Description:

Peritoneal dialysis patients are at increased risk of cardiovascular morbidity and mortality and are related to the presence of accelerated atherosclerosis. Other than the traditional cardiovascular risk factors, there is increasing evidence that inflammation is associated with the development of atherosclerosis and cardiovascular events in both the general and dialysis population. C-reactive protein is predictive of higher all-cause mortality and cardiovascular mortality, independent of other cardiovascular risk factors and atherosclerotic vascular disease. As a considerable proportion of peritoneal dialysis patients showed elevated C-reactive protein, it raises an important question as to whether lowering C-reactive protein will have any cardiovascular and survival benefit in these patients. On the other hand, insulin resistance with associated hyperinsulinemia is frequently observed in chronic renal failure and dialysis patients. Although the exact mechanism of insulin resistance needs further evaluation, studies indicated that insulin resistance is an important cardiovascular risk factor and outcome predictor in the general and dialysis population. Moreover, recent evidence indicates an association between chronic inflammation and insulin resistance although the exact interrelationship remains unclear. The peroxisome proliferator-activated receptor-gamma (PPAR-g) is a member of the nuclear receptor family of ligand-dependent transcription factors. PPAR-g is highly expressed in adipose tissue and clinical study has confirmed efficacy of the specific ligands for PPAR-gamma, namely thiazolidinediones (TZD), in improving insulin sensitivity. Recent experimental and clinical studies demonstrated that TZD has anti-inflammatory and anti-atherosclerotic properties other than insulin sensitizing effect in type 2 diabetics. We hypothesize that modulation of the PPAR-g activity may be a novel therapeutic strategy for reducing inflammation and improving insulin sensitivity and may retard the progression of atherosclerosis and possibly reduce mortality of our peritoneal dialysis patients.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 160
• Est. completion date: December 2014
• Est. primary completion date: October 2014
• Accepts healthy volunteers: No
• Gender: All
• Age group: 20 Years to 75 Years

Eligibility

Inclusion Criteria:

• Both prevalent patients or patients newly started on continuous peritoneal dialysis, with or without diabetes mellitus will be considered eligible for study entry.

• For patients newly started on chronic peritoneal dialysis, they will be suitable for recruitment into the study after one month on peritoneal dialysis.

• Patients who provide informed consent for the study

Exclusion Criteria:

• Patients with underlying active malignancy

• Patients with chronic liver disease or liver cirrhosis

• Patients with active infections

• Patients with other chronic active inflammatory disease such as systemic lupus erythematosus, rheumatoid arthritis

• Patients who refuse study participation

• Patients with underlying congenital heart disease or rheumatic heart disease

• Patients with poor general condition

• Patients with plans for living related kidney transplant within 2 years

• Female patients with pregnancy

• Patients with history of recurrent hypoglycemia

• Patients with Class III and IV congestive heart failure

• Patients already receiving glitazones treatment at the screening visit

Related Conditions & MeSH terms

• End-stage Renal Disease
• Kidney Failure, Chronic

Intervention

Drug:
• Pioglitazone
pioglitazone 15mg daily for 12 weeks, then 30mg daily for 84 weeks
• placebo comparator
1 capsule daily, 96 weeks.

Locations

Country	Name	City	State
Hong Kong	Queen Mary Hospital, Tung Wah Hospital	Hong Kong

Sponsors (2)

Lead Sponsor	Collaborator
The University of Hong Kong	Baxter Healthcare Corporation

Country where clinical trial is conducted

Hong Kong, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	overall survival	Hard outcome	over 96 weeks
Other	major adverse cardiovascular event-free survival	hard outcome	over 96 weeks
Other	Fluid overload/heart failure event-free survival	hard outcome	over 96 weeks
Other	myocardial infarction event-free survival	hard outcome	over 96 weeks
Other	3 point major adverse cardiovascular event-free survival	Hard outcome	over 96 weeks
Other	4 point major adverse cardiovascular event-free survival	Hard outcome	over 96 weeks
Primary	Change in carotid intima-media thickness	Change in carotid intima-media thickness	over 48 weeks
Primary	change in flow mediated dilatation (marker of endothelial function)	change in flow mediated dilatation (marker of endothelial function)	over 48 weeks
Secondary	change in aortic pulse wave velocity	change in aortic pulse wave velocity	over 96 weeks
Secondary	change in augmentation index-heart rate adjusted	change in augmentation index-heart rate adjusted	over 96 weeks
Secondary	change in nitroglycerin-mediated dilatation	change in nitroglycerin-mediated dilatation	over 48 weeks
Secondary	change in coronary artery calcium score	change in coronary artery calcium score	over 96 weeks
Secondary	change in heart valves calcium score	change in heart valves calcium score	over 96 weeks
Secondary	change in carotid artery calcium score	change in carotid artery calcium score	over 96 weeks
Secondary	change in abdominal visceral fat	change in abdominal visceral fat	over 96 weeks
Secondary	change in subcutaneous fat	change in subcutaneous fat	over 96 weeks
Secondary	change in blood pressure	change in blood pressure	over 96 weeks
Secondary	change in C-reactive protein	change in C-reactive protein	over 96 weeks
Secondary	change in residual kidney function	change in residual kidney function	over 96 weeks
Secondary	change in HOMA index (among those not on insulin)	Change in insulin resistance index	over 96 weeks
Secondary	change in D/P creatinine ratio	Change in peritoneal solute transport parameter	over 96 weeks
Secondary	change in peritoneal ultrafiltration with 2.5% during PET	Change in peritoneal ultrafiltration volume	over 96 weeks
Secondary	change in handgrip strength	change in handgrip strength	over 96 weeks
Secondary	Change in cardiac biomarkers	change in cardiac biomarkers	over 96 weeks
Secondary	change in insulin dose (among those on insulin)	change in insulin dose	over 96 weeks
Secondary	change in endothelial progenitor cells	change in endothelial progenitor cells	over 96 weeks
Secondary	change in central systolic blood pressure	change in central systolic blood pressure	over 96 weeks
Secondary	Change in central diastolic blood pressure	change in central diastolic blood pressure	over 96 weeks
Secondary	change in glycemic control (fasting glucose, and glycosylated hemoglobin)	change in glycemic control	over 96 weeks